Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

Vertex Pharmaceuticals has outperformed the broader healthcare sector over the past year. Despite a 6.3% drop from its ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...